Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTX Nkarta

Market Closed 11-13 16:00:00 EST

1.19

-0.07

-5.93%

盘后1.24

+0.05+3.78%

19:30 EST

High1.31	Low1.11	Vol1.41M
Open1.28	D1 Closing1.27	Amplitude15.88%
Mkt Cap85.14M	Tradable Cap71.93M	Total Shares71.55M
T/O1.66M	T/O Rate2.33%	Tradable Shares60.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTX","market":"US","secType":"STK","nameCN":"Nkarta","latestPrice":1.19,"timestamp":1794603600000,"preClose":1.265,"halted":0,"volume":1407214,"hourTrading":{"tag":"盘后","latestPrice":1.235,"preClose":1.19,"latestTime":"19:30 EST","volume":15837,"amount":19370.43,"timestamp":1794616201453,"change":0.045,"changeRate":0.037815,"amplitude":0.037815},"delay":0,"changeRate":-0.059288537549407085,"floatShares":60443200,"shares":71545358,"eps":-1.733931,"marketStatus":"Market Closed","change":-0.075,"latestTime":"11-13 16:00:00 EST","open":1.28,"high":1.3059,"low":1.105,"amount":1664307.3539938,"amplitude":0.158814,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.733931,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":1.265,"preHourTrading":{"tag":"盘前","latestPrice":1.3,"preClose":1.265,"latestTime":"08:45 EST","volume":493,"amount":633.119967,"timestamp":1794577526912,"change":0.035,"changeRate":0.027668,"amplitude":0.01581},"postHourTrading":{"tag":"盘后","latestPrice":1.235,"preClose":1.19,"latestTime":"19:30 EST","volume":15837,"amount":19370.43,"timestamp":1794616201453,"change":0.045,"changeRate":0.037815,"amplitude":0.037815},"volumeRatio":0.4751810208219012,"impliedVol":2.5795,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/NKTX","defaultTab":"news","newsList":[{"id":"2682301589","title":"Nkarta announces integrated safety results from 40 patients treated with NKX019","url":"https://stock-news.laohu8.com/highlight/detail?id=2682301589","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682301589?lang=en_us&edition=fundamental","pubTime":"2026-11-11 20:10","pubTimestamp":1794399030,"startTime":"0","endTime":"0","summary":"Nkarta (NKTX) announced integrated safety results from 40 patients treated with NKX019, an allogeneic, off-the-shelf, CD19-directed CAR NK cell the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-announces-integrated-safety-results-from-40-patients-treated-with-nkx019-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-announces-integrated-safety-results-from-40-patients-treated-with-nkx019-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","NKTX","BK4230","CAR","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682309193","title":"Nkarta Reports no Cytokine Release Syndrome in 40-Patient Nkx019 Autoimmune Trial Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2682309193","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682309193?lang=en_us&edition=fundamental","pubTime":"2026-11-11 20:04","pubTimestamp":1794398665,"startTime":"0","endTime":"0","summary":"Nkarta reports no cytokine release syndrome in 40-patient NKX019 autoimmune trial programNkarta presented initial NKX019 safety results from 40 patients across five autoimmune diseases at ACR Converge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nNDL1yN8MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","BK4139","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","NKTX","LU2210149790.SGD","IE00BQXX3F31.USD","LU2095319765.USD","LU2210150020.SGD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","BCDF","SG9999014039.USD","SG9999014013.SGD","BK4505","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682130915","title":"Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2682130915","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682130915?lang=en_us&edition=fundamental","pubTime":"2026-11-11 20:00","pubTimestamp":1794398400,"startTime":"0","endTime":"0","summary":"No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/11/3400583/0/en/nkarta-presents-initial-safety-data-for-nkx019-in-40-patients-across-five-autoimmune-diseases-at-acr-convergence-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","IBB","CNCR","GDOC","IBBQ","IE00B19Z4B17.USD","HYLG","BK4110","LFSC","CRS","BK4505","FBT","BK7508","SYNB","ACR.AU","LU0963586101.USD","BK7096","BK4139","XAR","BK9081","BK4187","IE0031619046.USD","CAR","NVIB","ACR","CAR.AU","MEDX","NKTX","PYZ","BK4022","IDNA","BK7095","085310.KR","IE00B7SZL793.SGD","TBXU","BK4006","BK4588","GNOM","BK4585","BK7503","LU2065731478.USD","BK7002","CRS.AU","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682380172","title":"Nkarta Price Target Maintained with a $11.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2682380172","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682380172?lang=en_us&edition=fundamental","pubTime":"2026-11-10 01:09","pubTimestamp":1794244140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682366800","title":"Nkarta Reports Moderate or Major Responses in 5 of 6 Myositis Patients in Nkx019 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2682366800","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682366800?lang=en_us&edition=fundamental","pubTime":"2026-11-09 20:10","pubTimestamp":1794226224,"startTime":"0","endTime":"0","summary":"Nkarta reports moderate or major responses in 5 of 6 myositis patients in NKX019 trialNkarta announced initial NKX019 trial results showing clinical improvement in most evaluable patients with treatme","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nNDLb5Zdtf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4505","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BCDF","LU2210150020.SGD","SG9999014005.SGD","BK4585","IE00BQXX3F31.USD","NDAQ","NKTX","SG9999014039.USD","BK4588","LU2210149790.SGD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4112","IE00B64PRP62.GBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682807643","title":"Nkarta, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2682807643","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682807643?lang=en_us&edition=fundamental","pubTime":"2026-11-09 20:00","pubTimestamp":1794225647,"startTime":"0","endTime":"0","summary":"Nkarta, Inc. reports results for the quarter ended September 30 - Earnings SummaryNkarta, Inc.NKTX.OQreported a quarterly adjusted loss of 45 cents per share for the quarter ended September 30, lower ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nL5N46Q13F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681946118","title":"Nkarta Hosts Webcast on Initial Nkx019 Clinical Data in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2681946118","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681946118?lang=en_us&edition=fundamental","pubTime":"2026-11-07 05:02","pubTimestamp":1793998959,"startTime":"0","endTime":"0","summary":"Nkarta Hosts Webcast on Initial NKX019 Clinical Data in Autoimmune DiseasesNkarta will host a webcast Nov. 9, 2026, at 8 a.m. ET to review initial NKX019 clinical data.The Ntrust program data cover my","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nNDLSWdBR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BQXX3D17.EUR","NKTX","SG9999014013.SGD","BK4112","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014021.USD","BK4139","IE00BGHQF748.EUR","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","LU0314104364.USD","BK4588","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4505","NDAQ","BCDF","BK4585","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681886695","title":"Nkarta Q3 2026 Net Loss Widens 53% to $33.33 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2681886695","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681886695?lang=en_us&edition=fundamental","pubTime":"2026-11-06 07:00","pubTimestamp":1793919632,"startTime":"0","endTime":"0","summary":"Nkarta Q3 2026 net loss widens 53% to $33.33 millionNkarta's third-quarter 2026 net loss widened 53% year over year to $33.33 million.Research and development expenses jumped 46% year over year to $29","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL5fKYjC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4505","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BCDF","LU2210150020.SGD","SG9999014005.SGD","BK4585","IE00BQXX3F31.USD","NDAQ","NKTX","SG9999014039.USD","BK4588","LU2210149790.SGD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4112","IE00B64PRP62.GBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681888459","title":"Nkarta Q3 EPS $(0.45) Misses $(0.42) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2681888459","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681888459?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:53","pubTimestamp":1793915580,"startTime":"0","endTime":"0","summary":"Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 55.17 percent decrease over losses of $(0.29) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62956065/nkarta-q3-eps-0-45-misses-0-42-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nkarta Q3 EPS $(0.45) Misses $(0.42) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681400018","title":"Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2681400018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681400018?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:34","pubTimestamp":1793914480,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nTUA7KSLGY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTX","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680862751","title":"Nkarta Coverage Assumed by HC Wainwright & Co. at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2680862751","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680862751?lang=en_us&edition=fundamental","pubTime":"2026-11-02 19:49","pubTimestamp":1793620140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670075239","title":"Nkarta (NKTX) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2670075239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670075239?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:56","pubTimestamp":1790592994,"startTime":"0","endTime":"0","summary":"In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Nkarta, with a price target of $10.00. According to TipR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nkarta-nktx-receives-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nkarta-nktx-receives-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143319","title":"H.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143319?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:45","pubTimestamp":1790070359,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Nkarta yesterday and set a price target of $14.00. The company’s shares closed yest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666600125","title":"Nkarta to Participate in September Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2666600125","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666600125?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to tre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359350/0/en/nkarta-to-participate-in-september-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665960322","title":"Nkarta to Present Initial Phase 1/2 Autoimmune Data for CAR-NK Therapy Nkx019 at ACR Convergence 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665960322","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665960322?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:01","pubTimestamp":1788865267,"startTime":"0","endTime":"0","summary":"Nkarta to present initial Phase 1/2 autoimmune data for CAR-NK therapy NKX019 at ACR Convergence 2026Nkarta flagged initial Phase 1/2 clinical readouts for CAR-NK therapy NKX019 across autoimmune dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL74Wb3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014039.USD","IE00BKPKM429.USD","BCDF","LU2095319765.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","SG9999014021.USD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","BK4139","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","BK4112","LU2210150020.SGD","NKTX","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","BK4585","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","BK4588","BK4505","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660399544","title":"Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660399544","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660399544?lang=en_us&edition=fundamental","pubTime":"2026-08-18 00:15","pubTimestamp":1786983336,"startTime":"0","endTime":"0","summary":"In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Nkarta, with a price target of $12.00. Syed covers the Hea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659673481","title":"Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2659673481","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659673481?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:20","pubTimestamp":1786652418,"startTime":"0","endTime":"0","summary":"Equillium Q2 post narrower net loss than expected; starts R&D initiativesOverviewUS biotech innovator's Q2 net loss narrowed and beat analyst expectationsQ2 loss per share beat analyst expectationsCom","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","EQ","BK4007","BK4139","ARTL","FATE","NKTX","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162295","title":"NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162295","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162295?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:11","pubTimestamp":1786651881,"startTime":"0","endTime":"0","summary":"NuCana Q2 loss narrows as clinical milestones remain on trackOverviewUK cancer drug developer's Q2 net loss narrowed to 3.1 mln from 24.1 mln yr/yrCompany ended Q2 with 19.5 mln in cash, expects runwa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A141:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4563","NCNA","PYXS","IMNM","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162459","title":"Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162459","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162459?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:09","pubTimestamp":1786651778,"startTime":"0","endTime":"0","summary":"Assembly Biosciences Q2 net loss narrows as revenue risesOverviewUS biotech firm's Q2 revenue from Gilead collaboration rose yr/yr, net loss narrowedLower net loss driven by higher revenue, reduced R&","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A13Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4505","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU0965509010.AUD","LU1057294990.SGD","LU0114720955.EUR","LU2468319806.SGD","LU0882574055.USD","LU0109394709.USD","BMED","SG9999015978.USD","IBBQ","LU0965508806.USD","TMED","TBXU","BK4588","IE00B7SZLL34.SGD","LU2087621335.USD","BK4139","LU0122379950.USD","LU1061106388.HKD","BK4007","LU1934455194.USD","LU1023059063.AUD","LU0889565916.HKD","NKTX","ASMB","LU0965509283.SGD","BK4566","BBH","AVIR","LU1674673428.USD","LU1674673691.USD","LU1585245621.USD","LU1571399168.USD","GILD","BIB","LU1934455277.USD","SG9999015986.USD","ARTL","LU0320765992.SGD","IBB","BK4578","IE00B19Z3581.USD","IE00B3T34201.USD","MEDI","LU2112291526.USD","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659971152","title":"Ovid Therapeutics Q2 Revenue Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659971152","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659971152?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:44","pubTimestamp":1786625080,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics Q2 revenue beats estimatesOverviewUS biopharma firm's Q2 revenue beat analyst expectationsCompany posted Q2 net loss as operating expenses rose on clinical study activityOvid secured","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRLD","OVID","CABA","BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nkartatx.com","stockEarnings":[{"period":"1week","weight":-0.3121},{"period":"1month","weight":-0.4138},{"period":"3month","weight":-0.4893},{"period":"6month","weight":-0.5492},{"period":"1year","weight":-0.367},{"period":"ytd","weight":-0.3568}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051655},{"month":2,"riseRate":0.5,"avgChangeRate":0.038672},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.082697},{"month":4,"riseRate":0.666667,"avgChangeRate":0.177626},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.08485},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.112595},{"month":7,"riseRate":0.833333,"avgChangeRate":0.046365},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.015599},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.057573},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.109469},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.037726},{"month":12,"riseRate":0.333333,"avgChangeRate":0.310979}],"exchange":"NASDAQ","name":"Nkarta","nameEN":"Nkarta"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nkarta,NKTX,Nkarta股票,Nkarta股票老虎,Nkarta股票老虎国际,Nkarta行情,Nkarta股票行情,Nkarta股价,Nkarta股市,Nkarta股票价格,Nkarta股票交易,Nkarta股票购买,Nkarta股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}